You are here: Industry Insights > HCC

News List

Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma prnasia
March 23, 2021
Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, announced full FDA approval of the DOORwaY90 Study, a trial evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin ...
Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma prnasia
February 09, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the first patient has ...
Q BioMed's Uttroside-B Receives Orphan Drug Designation for Liver Cancer americanpharmaceuticalreview
February 03, 2021
Q BioMed announced the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most ...
Roche’s Tecentriq/Avastin combo improves survival in liver cancer pharmatimes
January 14, 2021
Roche is planning to present updated data confirming that its immunotherapy combination, consisting of Tecentriq (atezolizumab) and Avastin (bevacizumab), improves overall survival (OS) in patients with a type of liver cancer.
New therapies will overcome unmet needs in hepatocellular carcinoma: GlobalData expresspharma
December 14, 2020
They have different mechanisms of action and are aiming to meet needs in different treatment settings.
Roche obtains EC approval for Tecentriq/Avastin to treat liver cancer pharmaceutical-technology
November 05, 2020
Roche has obtained approval from the European Commission for Tecentriq (atezolizumab) and Avastin (bevacizumab) combination to treat adult patients with advanced or unresectable hepatocellular carcinoma (HCC).
Eureka initiates trial to evaluate ET140203 ARTEMIS T Cell Therapy in HCC pharmaceutical-business-review
October 10, 2020
Eureka Therapeutics, Inc. announced the Company has initiated a Phase I/II clinical trial of its ET140203 ARTEMIS T cell therapy in adult patients with hepatocellular carcinoma (HCC), the predominant type of liver cancer.
TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatme prnasia
September 28, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases ...
FDA Approves Atezolizumab, plus Bevacizumab for Unresectable Hepatocellular Carcinoma americanpharmaceuticalreview
June 11, 2020
The Food and Drug Administration (FDA) has approved atezolizumab in combination with bevacizumab (TECENTRIQ and AVASTIN, Genentech Inc.) for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
Genentech gets FDA approval for Tecentriq, Avastin combo for HCC pharmaceutical-business-review
June 03, 2020
Genentech has secured approval from the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).

Previous page 1 2 3 4 Next page